期刊
JOURNAL OF IMMUNOLOGY
卷 189, 期 8, 页码 3905-3913出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1102152
关键词
-
类别
资金
- Korea Healthcare Technology Research and Development Project [A092258]
- Ministry for Health, Welfare, and Family Affairs
- National Research Foundation of Korea [R33-2008-000-10064-0, 2009-0080087]
- Ministry of Education, Science, and Technology
- National Institutes of Health Grant [R01 AR050498]
- Korea Health Promotion Institute [A092258] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- National Research Foundation of Korea [2009-0080087] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Macrophage migration inhibitory factor (MIF) is involved in tumorigenesis by facilitating tumor proliferation and evasion of apoptosis; however, its role in tumor immunity is unclear. In this study, we investigated the effect of MIF on the progression of the syngenic, CT26 colon carcinoma and the generation of tumor regulatory T cells (Tregs). The results showed that the tumor growth rate was significantly lower in MIF knockout (MIF-/-) mice than in wild-type (MIF+/+) mice. Flow cytometric analysis of both spleen and tumor cells revealed that MIF-/- mice had significantly lower levels of tumor-associated CD4(+)Tregs than MIF+/+ mice. The splenic cells of MIF-/- mice also showed a decrease in CD8(+)Tregs, which was accompanied by an increase in CD8-induced tumor cytotoxicity. Interestingly, the inducible Treg response in spleen cells to anti-CD3/CD28 plus IL-2 plus TGF-beta was greater in MIF-/- mice than in MIF+/+ mice. Spleen cells of MIF-/- mice, stimulated with anti-CD3/CD28, produced lower levels of IL-2, but not TGF-beta, than those of MIF+/+ mice, which was recovered by the addition of recombinant MIF. Conversely, a neutralizing anti-MIF Ab blocked anti-CD3-induced IL-2 production by splenocytes of MIF+/+ mice and suppressed the inducible Treg generation. Moreover, the administration of IL-2 into tumor-bearing MIF-/- mice restored the generation of Tregs and tumor growth. Taken together, our data suggest that MIF promotes tumor growth by increasing Treg generation through the modulation of IL-2 production. Thus, anti-MIF treatment might be useful in enhancing the adaptive immune response to colon cancers. The Journal of Immunology, 2012, 189: 3905-3913.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据